At the intersection of molecular biology and immunotherapy, researchers in South Korea have engineered a therapy that does not simply attack cancer but reorders the conversation cancer holds with the body. By learning to distinguish between the tumor's harmful molecular messengers and the immune system's beneficial ones, the EVOTAC nanoswitch selectively silences the former while amplifying the latter — achieving complete tumor elimination in animal models. It is early work, still far from the clinic, but it gestures toward a future in which cancer's own signaling machinery becomes the instrum
Novel 'nanoswitch' therapy eliminates tumors in animal models of breast and colorectal cancer
Turning cancer's own signals into weapons against itself
Mark
So the core insight here is that cancer cells release these vesicles, and some of them are actually helpful to the immune system?
Mimi
Exactly. That was the surprise. For years, researchers thought all tumor-derived vesicles were bad—they promote growth and metastasis. But it turns out some of them can trigger an immune response. The problem was that old drugs killed all of them indiscriminately.
Luke
But we should be clear: this is animal data. Mice and rats. We don't know yet if this precision control works the same way in human tumors, which are far more complex.
Mimi
True. But what's striking is the completeness of the effect in the models they tested. Complete tumor elimination is rare in early research.
Mark
How does the laser part work exactly? Is that something a surgeon would have to do?
Mimi
It's photodynamic therapy—a light-activated drug that generates reactive oxygen species. The laser activates it at the tumor site. In theory, yes, it would require localized application, which is feasible for accessible tumors.
Luke
The question is whether you can deliver this reliably in a living human body, and whether the immune activation they're seeing in mice translates to durable protection in people.
Mark
What makes this different from checkpoint inhibitors or CAR-T therapies that are already in the clinic?
Mimi
Those work by releasing the brakes on the immune system. This approach is more targeted—it's eliminating the specific molecular signals cancer cells use to hide, then forcing them to produce vesicles that activate immunity. It's a different mechanism entirely.
Luke
And it's worth noting: this is one research group's work in one publication. We'd want to see independent replication before drawing conclusions about clinical potential.
Le Pouls
- Cancer cells have long exploited tiny molecular packets called extracellular vesicles to suppress immunity and spread — and existing therapies that block all vesicles indiscriminately have been undermining the very defenses they aim to protect.
- The EVOTAC system introduces a two-stage nanoswitch: first dismantling the proteins that produce harmful vesicles, then using laser-activated therapy to coax tumor cells into generating immune-activating ones instead.
- In animal models of triple-negative breast cancer and colorectal cancer — two of oncology's most resistant targets — tumors were completely eliminated, with immune responses suppressing both recurrence and metastasis.
- The technology now faces the long and uncertain road of human clinical trials, where the precision that worked in animals must prove itself in the vastly more complex terrain of human biology.
At the intersection of molecular biology and immunotherapy, researchers in South Korea have engineered a therapy that does not simply attack cancer but reorders the conversation cancer holds with the body. By learning to distinguish between the tumor's harmful molecular messengers and the immune system's beneficial ones, the EVOTAC nanoswitch selectively silences the former while amplifying the latter — achieving complete tumor elimination in animal models. It is early work, still far from the clinic, but it gestures toward a future in which cancer's own signaling machinery becomes the instrument of its undoing.
Scientists at Sungkyunkwan University, collaborating with Korean research institutes, have developed a cancer therapy that operates like a molecular light switch — selectively silencing the signals that help tumors thrive while amplifying those that call the immune system to arms. Their system, called EVOTAC, targets extracellular vesicles: nanoscale packets that cancer cells release to manipulate their environment.
The core problem the team confronted was one of precision. Cancer-derived vesicles play contradictory roles — some shield tumors from immune detection, while others can actually provoke an anticancer response. Drugs that broadly suppress all vesicles eliminate the harmful ones but also destroy the beneficial, leaving the immune system disarmed. EVOTAC was designed to make that distinction.
The therapy works in two phases. First, it degrades specific proteins inside cancer cells, halting the production of tumor-promoting vesicles and resetting the molecular environment around the tumor. Then, a localized laser triggers photodynamic therapy, destroying cancer cells through reactive oxygen species — and crucially, prompting the dying tumor cells to release a different class of vesicles, ones capable of activating immune defenses rather than suppressing them.
Tested in animal models of triple-negative breast cancer and colorectal cancer, the results were unambiguous: complete tumor elimination, with immune activation that suppressed both recurrence and spread. The researchers describe the approach as a new paradigm — one that treats the tumor's own signaling system as simultaneously a vulnerability to exploit and a weapon to redirect. Clinical trials in humans remain ahead, but the precision and completeness of these early results have drawn significant attention as a potential foundation for next-generation immunotherapy.
Scientists at Sungkyunkwan University, working with colleagues at the Korea Institute of Science and Technology and Incheon National University, have engineered a new cancer therapy that works by turning harmful molecular signals on and off like a switch. The approach, published in Signal Transduction and Targeted Therapy, targets tiny vesicles—nanoscale packets of material—that cancer cells release into the body, and it has eliminated tumors entirely in animal models of triple-negative breast cancer and colorectal cancer.
The challenge the team was trying to solve is deceptively simple to state but difficult to execute. Cancer cells release extracellular vesicles, small membrane-bound structures that carry proteins and other molecules. Some of these vesicles help the tumor grow, spread, and hide from the immune system. Others, it turns out, can actually trigger an immune response against cancer. Existing drugs have tried to solve this problem by broadly suppressing all extracellular vesicles—essentially shutting down the entire communication system. But that approach backfires. By blocking all vesicles indiscriminately, these treatments also eliminate the beneficial ones that could activate the body's defenses. The result is a therapy that undermines its own purpose.
What the Sungkyunkwan team developed instead is a two-stage intervention they call EVOTAC, a nanoswitch-based agent that operates with surgical precision. In the first phase, the therapeutic targets and degrades specific intracellular proteins inside cancer cells, eliminating the production of harmful, tumor-promoting vesicles and resetting the environment around the tumor. Then comes the switch. The researchers apply a localized laser to the tumor site, triggering photodynamic therapy—a process in which a light-activated drug generates reactive oxygen species that destroy cancer cells. But here is where the strategy diverges from conventional approaches: in response to this laser treatment, the tumor cells preferentially produce a different class of extracellular vesicles, ones that are immunogenic—capable of activating anticancer immunity.
When the team tested this nanoswitch strategy in animal models, the results were unambiguous. Tumors were completely eliminated. The activation of anticancer immune responses effectively suppressed both recurrence and metastasis. The researchers achieved this outcome only after extensive trial and error, learning to precisely control extracellular vesicles as both a therapeutic target and an immune-modulating tool simultaneously.
The significance of this work extends beyond the immediate results. By demonstrating that tumor-derived extracellular vesicles can function as both a treatment target and an immune regulator, the study presents what the researchers describe as a new paradigm in cancer immunotherapy. It suggests that future therapies might exploit the same dual nature of these vesicles—using them as a vulnerability to attack while also harnessing them as a way to mobilize the immune system. The work is early-stage; animal models do not always translate to human benefit, and clinical trials remain ahead. But the precision of the approach and the completeness of the tumor elimination in these models has positioned the research as a potential foundation for the next generation of cancer treatments.
Citations marquantes
The study presents a new paradigm in cancer immunotherapy by demonstrating that tumor-derived extracellular vesicles can serve simultaneously as a treatment target and an immune regulator.— Research team findings
Envie de l'histoire complète ?
Lire l'original sur Medical Xpress ↗
Health & Medicine